Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France: Support for primary HDV screening in France.
Fiche publication
Date publication
février 2024
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François
Tous les auteurs :
Parfut A, Tripon S, Gantner P, Chaffraix F, Laugel E, Wendling MJ, Erol F, Wiedemer C, Doffoel M, Saviano A, Royant M, Habersetzer F, Fafi-Kremer S, Velay A
Lien Pubmed
Résumé
Hepatitis Delta virus (HDV) infection is a major cause of liver-related morbidity and mortality in patients infected with HBV, with a global HDV prevalence uncertain. In France, 2 to 5 % of HBs antigen (HBsAg) carriers present anti-HDV antibodies (anti-HDV). The EASL recommends testing for anti-HDV in all HBsAg-positive patients. Since January 2022, we have systematically carried out anti-HDV serology when a positive HBsAg is discovered (new HBsAg carriers).
Mots clés
HDV prevalence, Hepatitis D virus, Reflex testing
Référence
J Clin Virol. 2024 02 3;171:105650